Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Holding ALNY?
Track your performance easily

Alnylam Pharma (ALNY) Ownership - Who Owns Alnylam Pharma?

1,168 Followers

Alnylam Pharma (ALNY) Ownership Overview

0.37%48.38%0.77%15.20%35.27%
0.77% Other Institutional Investors
15.20% ETFs
35.27% Public Companies and Individual Investors
The ownership structure of Alnylam Pharma (ALNY) stock is a mix of institutional, retail, and individual investors. Approximately 64.36% of the company’s stock is owned by Institutional Investors, 0.37% is owned by Insiders, and 35.27% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 26, 2024
Pushkal Garg
Cmo & Evp Dev & Med Affairs
xxxxxxxxxxxxx
$485773
Jun 26, 2024
Yvonne Greenstreet
Ceo,director
xxxxxxxxxxxxx
$1917475
Jun 26, 2024
Fitzgerald Kevin Joseph
Cso & Evp, Head Of Research
xxxxxxxxxxxxx
$276731
Jun 26, 2024
xxxxxxxxxxxxx
$370747

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
12,032,771Institution9.33%3,295,896,305
11,130,048Institution8.63%3,048,631,448
10,609,427Institution8.23%2,906,028,150
4,927,057Institution3.82%1,349,570,183
4,107,472Institution3.18%1,125,077,656
3,780,185Institution2.93%1,035,430,473
3,424,200Institution2.65%937,922,622
2,953,386Institution2.29%808,961,959
2,850,341Institution2.21%780,736,903
2,429,100Institution1.88%665,354,781

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
11,130,048Institution8.63%3,048,631,448
10,609,427Institution8.23%2,906,028,150
4,927,057Institution3.82%1,349,570,183
3,424,200Institution2.65%937,922,622
2,953,386Institution2.29%808,961,959
2,850,341Institution2.21%780,736,903
2,429,100Institution1.88%665,354,781
2,331,102Institution1.81%638,512,149
1,705,722Institution1.32%467,214,313
1,524,500Institution1.18%417,575,795

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,071,215Institution3.16%1,119,706,261
2,718,825Institution2.11%747,758,440
1,916,658Institution1.49%527,138,450
1,445,922Institution1.12%397,671,928
904,086Institution0.70%248,650,773
895,531Institution0.69%245,294,896
703,933Institution0.55%187,661,498
613,128Institution0.48%167,941,890
420,427Institution0.33%115,630,038
402,251Institution0.31%110,180,571

FAQ

Who Owns Alnylam Pharmaceuticals (ALNY)?
According to the latest TipRanks data, approximately 0.77% of the company's stock is held by institutional investors, 0.37% is held by insiders, and 35.27% is held by retail investors.
    What percentage of Alnylam Pharmaceuticals (ALNY) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 0.77% of Alnylam Pharmaceuticals (ALNY) stock is held by institutional investors.
      What percentage of Alnylam Pharmaceuticals (ALNY) stock is held by retail investors?
      According to the latest TipRanks data, approximately 35.27% of Alnylam Pharmaceuticals (ALNY) stock is held by retail investors.
        Who owns the most shares of Alnylam Pharmaceuticals (ALNY)?
        Vanguard owns the most shares of Alnylam Pharmaceuticals (ALNY).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis